Key Takeaways BMY will give Eliquis free to Medicaid and donate more than 7 tons of its active ingredient. Eliquis is Bristol Myers Squibb's top drug, posting $11B in sales in the first nine months of 2025. The government deal grants BMY three years of tariff relief and no future pricing mandates.Bristol Myers Squibb (BMY) announced a pricing agreement with the U.S. government to supply Eliquis (apixaban) at no cost to Medicaid beginning Jan. 1, 2026. BMY will also donate more than 7 tons of the active phar ...

The pill is 25 milligrams of semaglutide, the same active ingredient in injectable Wegovy and Ozempic, and will be sold under the brand name Wegovy. Novo already sells an oral semaglutide for type 2 diabetes, Rybelsus. The U.S. Food and Drug Administration approved Novo Nordisk's weight-loss pill on Monday, giving the Danish drugmaker a leg up in the race to market a potent oral medication for shedding pounds as it looks to regain lost ground from rival Eli Lilly. The approval could help spur a turnaround f ...

Core Insights - BioMarin Pharmaceutical Inc. has acquired Amicus Therapeutics for $4.8 billion to enhance its market position in the rare genetic diseases sector against competitors like Alexion Pharmaceuticals and Vertex Pharmaceuticals [1][4] Acquisition Details - The acquisition involves purchasing all outstanding shares of Amicus at $14.50 per share, representing a 33% premium over its previous closing price [5] - The deal is financed through BioMarin's cash reserves and $3.7 billion in non-convertible debt, strategically avoiding equity dilution [2][6] - The acquisition is expected to close in the second quarter of 2026 and will add Amicus' therapies, Galafold and Pombiliti-Opfolda, which generated $449 million in sales in the first nine months of 2025, to BioMarin's portfolio [5][6] Market Reaction - Following the acquisition announcement, BioMarin's stock surged by 18%, while Amicus' stock increased by 30%, indicating strong investor confidence in the strategic benefits of the acquisition [2][7] - Joon Lee from Truist Financial set a price target of $100 for BioMarin, suggesting a potential upside of 68.7% from its trading price of $59.28 at the time of the announcement [4]

The approval of Novo Nordisk's (NYSE:NVO) oral Wegovy is bringing new interest to health care and pharmaceutical ETFs that provide access to the growing GLP-1 market without requiring investors to choose one specific company.• What should traders watch with XLV?Broad funds like the Health Care Select Sector SPDR Fund (NYSE:XLV) and the Vanguard Health Care ETF (NYSE:VHT) offer diversified exposure to major drugmakers, such as Novo Nordisk and Eli Lilly And Co (NYSE:LLY) , as well as insurers and health care ...

Core Insights - Significant investors have adopted a bearish stance on Merck & Co, with 53% of trades being bearish and 46% bullish [1] - The predicted price range for Merck & Co over the last three months is between $90.0 and $110.0 [2] Options Trading Activity - A total of 13 trades were detected for Merck & Co, with 6 puts amounting to $623,040 and 7 calls totaling $278,124 [1] - Noteworthy options activity includes several bearish trades, with significant put options at strike prices of $90.00, $95.00, and $105.00, indicating a bearish sentiment among traders [7] Market Position and Analyst Ratings - Merck & Co's current market position is supported by expert opinions, with an average target price of $119.4 from 5 analysts [9] - Analysts from various firms have differing ratings, with Morgan Stanley maintaining an Equal-Weight rating at $102, while BMO Capital upgraded to Outperform with a target of $130 [10] Company Overview - Merck & Co specializes in pharmaceutical products across various therapeutic areas, including cancer and cardiometabolic diseases, with Keytruda being a major sales contributor [8] - The company generates 47% of its sales from the US human health sector, which includes pharmaceuticals and vaccines [8] Trading Metrics - The trading volume for Merck & Co stands at 7,080,902, with the stock price at $104.99, reflecting a 0.26% increase [12] - The upcoming earnings announcement is expected in 42 days, indicating a potential catalyst for stock movement [12]

Core Viewpoint - The article discusses top dividend stock picks for the upcoming year, highlighting a diverse selection across different sectors, including a REIT, materials, energy, and healthcare stocks, aimed at providing stable income regardless of market conditions [1][3]. Group 1: Stock Selections - Amcor is highlighted for its recent merger with Barry, projecting 13% earnings growth next year and 11% the following year, and is considered a dividend aristocrat [4]. - Bristol Myers is noted for its strong cash flow and potential for earnings growth, although its growth is expected to materialize further out [2][4][16]. - Enbridge, a major pipeline company with 40,000 miles of oil and gas pipelines, is positioned to benefit from ongoing energy demand without being overly exposed to oil and gas price cycles [5]. - Vichy, primarily a REIT focused on casinos, maintained 100% occupancy during the pandemic and is currently trading nearly 10% below its recent high, offering a 6.4% yield [6][9]. Group 2: Market Context and Performance - The selected stocks generally yield around 6%, with Bristol Myers yielding approximately 4.5%, and all are trading at about 10 times earnings [2]. - The healthcare sector, particularly for Bristol Myers, is expected to see improved clarity and appreciation due to ongoing discussions around drug pricing [5]. - Vichy's stock performance has been impacted by perceptions of weakness in Las Vegas, despite its strong occupancy rates and long-term leases with high-quality tenants [7][11]. Group 3: Dividend Strategy and Economic Considerations - The discussion emphasizes the importance of dividend income, especially in a context of potentially higher interest rates, suggesting that dividends may still provide better income growth compared to treasury yields [18][19]. - The historical growth rate of dividend income is noted to be around 5.5%, aligning with the S&P's dividend growth, making dividend-paying stocks attractive for income-seeking investors [19]. - Companies like Amcor face challenges in assessing their debt portfolios and interest expenses in a rising rate environment, particularly with significant maturities approaching in 2027 [20][21].

Markets are flat early Tuesday in holiday-thinned trading before head of the release of new data on how the U.S. economy fared in the third quarter. Futures for the S&P 500, the Dow Jones Industrial Average and Nasdaq are all essentially unchanged before the opening bell. Shares of the Danish pharmaceutical company Novo Nordisk jumped more than 7% overnight after U.S. regulators approved a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. Novo's Wegov ...

HSBC's senior research analyst Rajesh Kumar believes Novo Nordisk (NYSE: NVO) "might have an edge†over rival Eli Lilly (NYSE: LLY) heading into 2026. His remarks arrive shortly after the Danish pharm... ...

Yesterday, the Food and Drug Administration (FDA) approved Novo Nordisk 's ( NYSE:NVO ) Wegovy weight-loss pill, the first of its kind. ...

Wall Street traded modestly higher Wednesday, with large-cap benchmarks attempting a fourth straight day of gains as investors looked ahead to a seasonally strong year-end stretch.By midday in New York, the S&P 500 was up 0.4% near 6,900, hovering within striking distance of last October's all-time highs at 6,920. The Nasdaq 100 also added 0.4%, while the Dow Jones Industrial Average climbed 0.3%. Small caps lagged, with the Russell 2000 down about 0.6%.The session was shaped by the release of stronger-than ...